Market Overview
According to fortune business insights, the global lupus nephritis drugs market size was valued at USD 1.90 billion in 2025. The market is projected to grow from USD 2.12 billion in 2026 to USD 4.64 billion by 2034, exhibiting a CAGR of 10.28% during the forecast period. Asia Pacific dominated the lupus nephritis drugs market with a market share of 48.42% in 2025.
The analysis shows that top companies are receiving new regulatory approvals as the focus on treating kidney involvement in lupus patients grows. For example, in June 2025, GSK plc received U.S. FDA approval for its Benlysta autoinjector for patients aged five and older, improving treatment convenience. This trend indicates strong demand for innovative and effective therapies worldwide.
Major Players Profiled in the Market Report:
Segments
Growing Adoption of Targeted B-Cell Therapies to Propel Monoclonal Antibody Segment Growth
Based on drug type, the market is divided into monoclonal antibody, immunosuppressant, and corticosteroids. The monoclonal antibody segment holds the largest market share and dominates the market owing to the increasing use of targeted B-cell therapies like belimumab in combination with conventional treatments.
High Disease Prevalence and Intensity to Drive Class 4 Segment Expansion
By disease type, the market is categorized into Class 3 (Focal), Class 4 (Diffuse), and Class 5 (Membranous). The Class 4 segment is leading the market as it is highly prevalent among patients and is associated with extensive kidney inflammation that requires intensive and prolonged treatment.
Established Use in Long-Term Therapy to Dominate Oral Route Segment
Based on route of administration, the market is segmented into oral and parenteral. The oral segment holds the largest market share owing to its practicality for the prolonged induction and maintenance therapy required for lupus nephritis, with core treatments like calcineurin inhibitors being administered orally.
Specialist-Led Treatment to Propel Hospital Pharmacy Segment Growth